Given that gene mutations (KRAS, BRAF and PIK3CA) influence cetuximab sensitivity, we chose two cell lines (Caco-2 and DiFi) that express wild-type KRAS, BRAF and PIK3CA, paralleling the molecular features of colon cancer patients who are most likely to respond to cetuximab (Supplementary Table S1). This evidence concerns the gene KRAS and malignant colon neoplasm.